Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group

References

• Valent P, Horny HP, Bennett JM, . Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727–736.
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht AA, Alhan C, Bene MC, . Standardization of flow cytometry in myelodysplastic syndromes:report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009;94:1124–1134.
   PubMed Web of Science ®Google Scholar
• Westers TM, Ireland R, Kern W, . Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.Leukemia 2012;26:1730–1741.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD.The World Health Organization (WHO) classification of the myeloid neoplasms.Blood 2002;100:2292–2302.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Della Porta MG, Pascutto C, . Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.J Clin Oncol 2005;23:7594–7603.
   PubMed Web of Science ®Google Scholar
• van de Loosdrecht AA, Westers TM, Westra AH, . Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.Blood 2008;111: 1067–1077.
   PubMed Web of Science ®Google Scholar
• Stachurski D, Smith BR, Pozdnyakova O, . Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls.Leuk Res 2008;32:215–224.
   PubMed Web of Science ®Google Scholar
• Brunning R, Orazi A, Germing U, et al. Myelodysplastic syndromes/neoplasms. In: Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours and haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 88–147.
   Google Scholar
• Wimazal F, Fonatsch C, Thalhammer R, . Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface.Leuk Res 2007;31:1461–1468.
   PubMed Web of Science ®Google Scholar
• Valent P, Horny HP.Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.Eur J Clin Invest 2009;39:548–553.
   PubMed Web of Science ®Google Scholar
• Truong F, Smith BR, Stachurski D, . The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: a prospective study.Leuk Res 2009;33: 1039–1046.
   PubMed Web of Science ®Google Scholar
• Ogata K, Della Porta MG, Malcovati L, . Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study.Haematologica 2009;94:1066–1074.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Ogata K, Picone C, . Multicentric validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study.Haematologica 2012;97:1209–1217.
   PubMed Web of Science ®Google Scholar
• Wells DA, Benesch M, Loken MR, . Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.Blood 2003;102:394–403.
   PubMed Web of Science ®Google Scholar
• Ogata K, Kishikawa Y, Satoh C, . Diagnostic application of flow cytometric characteristics of CD34+cells in low-grade myelodysplastic syndromes.Blood 2006;108:1037–1044.
   PubMed Web of Science ®Google Scholar
• Scott BL, Wells DA, Loken MR, . Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.Blood 2008;112: 2681–2686.
   PubMed Web of Science ®Google Scholar
• Matarraz S, Lopez A, Barrena S, . The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors.Leukemia 2008;22: 1175–1183.
   PubMed Web of Science ®Google Scholar
• Matarraz S, Lopez A, Barrena S, . Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease:a pilot study on A series of 56 patients.Cytometry B Clin Cytom 2010;78:154–168.
   PubMed Web of Science ®Google Scholar
• Schanz J, Tuchler H, Sole F, . New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.J Clin Oncol 2012;30:820–829.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Tuechler H, Schanz J, . Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes.Blood2012 Jun 27. [Epub ahead of print]
   Google Scholar
• Germing U, Hildebrandt B, Pfeilstocker M, . Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).Leukemia 2005;19:2223–2231.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Germing U, Kuendgen A, . Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.J Clin Oncol 2007;25: 3503–3510.
   PubMed Web of Science ®Google Scholar
• Langemeijer SM, Kuiper RP, Berends M, . Acquired mutations in TET2 are common in myelodysplastic syndromes.Nat Genet 2009; 41:838–842.
   PubMed Web of Science ®Google Scholar
• Nikoloski G, Langemeijer SM, Kuiper RP, . Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.Nat Genet 2010;42:665–667.
   PubMed Web of Science ®Google Scholar
• Valent P, Orazi A, Busche G, . Standards and impact of hematopathology in myelodysplastic syndromes (MDS).Oncotarget 2010;1:483–496.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Malcovati L, Strupp C, . Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.Haematologica 2011;96: 441–449.
   PubMed Web of Science ®Google Scholar
• Schanz J, Steidl C, Fonatsch C, . Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.J Clin Oncol 2011;29:1963–1970.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, . Frequent pathway mutations of splicing machinery in myelodysplasia.Nature 2011;478:64–69.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson K, bdel-Wahab O, . Clinical effect of point mutations in myelodysplastic syndromes.N Engl J Med 2011;364: 2496–2506.
   PubMed Web of Science ®Google Scholar
• Malcovati L, Papaemmanuil E, Bowen DT, . Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Blood 2011;118: 6239–6246.
   PubMed Web of Science ®Google Scholar
• Cutler JA, Wells DA, van de Loosdrecht AA, . Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopenias.Cytometry B Clin Cytom 2011;80:150–157.
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach C, Schnittger S, . Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data.Cancer 2010;116:4549–4563.
   PubMed Web of Science ®Google Scholar
• Chu SC, Wang TF, Li CC, . Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes.Leuk Res 2011;35:868–873.
   PubMed Web of Science ®Google Scholar
• Kordasti SY, Ingram W, Hayden J, . CD4+CD25high Foxp3+regulatory T cells in myelodysplastic syndrome (MDS).Blood 2007;110:847–850.
   PubMed Web of Science ®Google Scholar
• Epling-Burnette PK, Bai F, Painter JS, . Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.Blood 2007;109:4816–4824.
   PubMed Web of Science ®Google Scholar
• Chamuleau ME, Westers TM, van Dreunen L, . Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.Haematologica 2009;94:496–506.
   PubMedGoogle Scholar
• Kordasti SY, Afzali B, Lim Z, . IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome.Br J Haematol 2009;145:64–72.
   PubMed Web of Science ®Google Scholar
• Westers TM, Alhan C, Chamuleau MED, . Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.Blood 2010;115:1779–1784.
   PubMed Web of Science ®Google Scholar
• Frisan E, Pawlikowska P, Pierre-Eugene C, . p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes.Haematologica 2010;95: 1964–1968.
   PubMed Web of Science ®Google Scholar
• Westers TM, Alhan C, Cali C, . Quantitative dynamics of flow cytometric aberrancies during treatment with erythropoietin/ G-CSF are predictive for responses in low/Int-1 risk myelodysplastic syndromes.Blood 2008;112(Suppl. 1): Abstract 586.
   Google Scholar
• Silverman LR, Fenaux P, Mufti GJ, . Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.Cancer 2011; 117:2697–2702.
   PubMed Web of Science ®Google Scholar